Please login to the form below

Not currently logged in
Email:
Password:

Aristada

This page shows the latest Aristada news and features for those working in and with pharma, biotech and healthcare.

Rare disease therapies head the ‘class of 2015’

Rare disease therapies head the ‘class of 2015’

Praluent. hypercholesterolaemia. PCSK9 inhibitor. Regeneron/Sanofi. USA. aripiprazole lauroxil. Aristada. schizophrenia. atypical antipsychotic (D2 partial agonist).

Latest news

  • Alkermes depression drug misses targets in phase III Alkermes depression drug misses targets in phase III

    Alkermes is in the throes of launching its new long-acting schizophrenia treatment Aristada (aripiprazole lauroxil), which was approved by the FDA in October.

  • FDA approves Alkermes’ long-acting Abilify FDA approves Alkermes’ long-acting Abilify

    Aristada given the nod as injectable antipsychotic. Alkermes' Aristada (aripiprazole lauroxil) has been approved by the FDA as a long-acting injectable version of Abilify. ... The approval of Aristada will come as further bad news to Otsuka as Abilify

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...

Infographics